InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article contentBEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase II/III clinical trial of novel TYK2 inhibitor soficitinib (ICP-332) for the treatment of chronic spontaneous urticaria (CSU).Sign In or Create an AccountEmail AddressContinueor View more offersArticle contentCurrently, patient enrollment has been completed in the Phase III registrational clinical trial of soficitinib for the treatment of moderate to severe atopic dermatitis (AD), and in the Phase II clinical trial for the treatment of vitiligo. In addition, clinical trials of soficitinib for the treatment of psoriasis and nodular prurigo are also progressing rapidly.Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.Article contentArticle contentSoficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders. The current indications under development are strategically positioned within the vast dermatology market. TYK2 plays a key role in the JAK-STAT signaling pathway and is critical in the pathogenesis of inflammatory diseases.Article contentTop StoriesGet the latest headlines, breaking news and columns.There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.Article contentSoficitinib blocks signaling pathways such as lL-4, IL-13, IL-31, and other cytokines that drive mast cell activation and inflammation, reducing itch and wheals in CSU.Article contentCSU is characterized by recurrent wheals and itch, with a disease course typically lasting two to five years, and in some patients, even exceeding five years. China has a large population of CSU patients, and the condition is prone to recurrent episodes. Intense nighttime itching can severely disrupt patients’ daily lives. Long-term, systematic, and standardized treatment is therefore essential for disease control.Article contentThere are approximately 50 million CSU patients worldwide1, and the global CSU treatment market is expected to reach $3 billion in 20292.Article contentArticle contentDr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, “We are delighted to see the rapid progress of our five clinical trials for the TYK2 inhibitor. We hope this innovative drug will benefit more autoimmune patients as soon as possible and address their significant unmet medical needs.”Article contentAbout InnoCareArticle contentInnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.Article contentContact MediaInvestorsChunhua Lu 86-10-6660987986-10-66609999chunhua.lu@innocarepharma.comir@innocarepharma.comArticle content1 DOI: 10.1007/s12325-025-03172-02 The Business Research CompanyArticle contentArticle contentArticle contentArticle contentArticle contentArticle contentTrending Ontario issues first permit that opens up old mine tailings for exploration Mining As U.S. companies return to Venezuela's oilfields — one Canadian driller has a head start Oil & Gas CRA charged taxpayer instalment interest before he received all his GIC income Taxes As Canadian bond yields fall, watch for fixed rates to follow Mortgage Rates For some Canadian travellers in Cuba, getting home is not so easy Airlines Share this article in your social networkCommentsYou must be logged in to join the discussion or read more comments.Create an AccountSign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. Ontario issues first permit that opens up old mine tailings for exploration Mining As U.S. companies return to Venezuela's oilfields — one Canadian driller has a head start Oil & Gas CRA charged taxpayer instalment interest before he received all his GIC income Taxes As Canadian bond yields fall, watch for fixed rates to follow Mortgage Rates For some Canadian travellers in Cuba, getting home is not so easy Airlines